This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Nov. 16, 2011 /PRNewswire/ --
Vista Partners announced today that it has updated coverage on
Cellmid Ltd. (ASX: CDY) (the "Company") and raised its twelve month target price to AUD
Ross Silver, Principal Analyst at Vista Partners stated, "Cellmid is on track to enter clinical trials for its AMI indication with a market estimated to be in the billions. The Company recently completed humanisation of its "first in class" anti-midkine antibody, hu91, in collaboration with
Antitope Ltd. The humanisation has been completed on time and within budget and resulted in a drug that can enter clinical development. This is the most significant milestone to date in the Company's antibody program and has removed a substantial risk from the clinical development path." Mr. Silver continued, "Cellmid has a large portfolio of patents surrounding midkine and owns 21 patent families worldwide. Cellmid plans to monetize this portfolio through two segments: Diagnostics and Therapeutics. The Diagnostic programs are in a more advanced stage and are poised to face regulatory approvals first. The Therapeutic programs are in pre-clinical trials; however they involve high value antibody candidates with early partner/licensing potential."
To download a FREE copy of the
Cellmid Ltd. research report, please visit
www.vistapglobal.com and complete the research form to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of
Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of
profitable investment ideas.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website
www.vistapglobal.com or click
SOURCE Vista Partners